Clinical trials for 2-IB (2-iminobiotin) are now underway and will reveal whether NOS inhibition can be used as a therapeutic treatment for perinatal asphyxia [22,23,24,25,26,27,28]. Here, NOS2 is linked to perinatal asphyxia.